Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Cystic Fibrosis Clinical Trials

A listing of Cystic Fibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (18) clinical trials

Study Assessing the Safety Tolerability Pharmacokinetics Food Effect and Drug-Drug Interactions of PTI-801 in Healthy Volunteers and Safety Tolerability and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

PART 1 The SAD treatment group is comprised of three cohorts where HV will be randomized to either PTI-801 or placebo. Following the conclusion of at least three SAD cohorts, a set of HV will participate in an assigned MAD treatment group. The MAD treatment group is comprised of three ...


A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects

This is an open-label, non-randomised, single-sequence 2-part study. Enrolment into Part 2 of the study will begin after Part 1 is complete, and a review of safety and pharmacokinetic data has been completed.Part 1 will assess the safety, tolerability and pharmacokinetics of single doses of FDL176 with and without co-administration ...


Study Assessing PTI-428 Safety Tolerability and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO as Background Therapy

The single treatment group will enroll adult subjects with CF currently on stable KALYDECO background therapy for a minimum of 3 months at the time of randomization. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 14 Days. ...


Clearance of 25-hydroxyvitamin D in Cystic Fibrosis

The goal of this study is to define 25(OH)D3 catabolism in CF patients using gold standard pharmacokinetics studies. Specifically, the investigators will evaluate the metabolic clearance of 25(OH)D3 among participants with CF and matched control subjects. The goal of this work is to provide the first comprehensive characterization of vitamin ...


Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis

This will be a prospective, single-center, dose-escalation, open-label interventional study to evaluate the safety and tolerability of allogeneic hMSCs in 15 clinically stable subjects with CF age 18 years. After a two to six week screening period, subjects will have a Baseline visit (Days 1-2) where they will undergo a ...


Airway Alkalinization and Nasal Colonization

16 subjects per group will be randomized to receive study drug or saline followed by a wash out period and cross-over to the other treatment, three times daily for 4 days. Nasal swab will be done at baseline and after both study treatment and saline treatment for assessment of airway ...


First-in-man Dose Escalation Study of ALX-009 and Its Components in Healthy Men and Cystic Fibrosis Suffering Patients

Part I: SAD of OSCN- and bLF in healthy male volunteers (cohorts 1 to 3) - Part II: SAD and MAD of ALX-009 in healthy male volunteers (cohorts 4 and 5) - Part III: MAD of OSCN- and bLF in patients suffering from cystic fibrosis (cohorts 6 to 8) - ...


Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation

The investigators have developed a new therapy utilizing a stem cell found in the bone marrow that is defined by cell surface expression of the protein "cluster of differentiation antigen 117" (CD117). Studies utilizing these stem cells in a mouse heart transplant model have demonstrated significantly improved survival of transplanted ...


MAD Study Evaluating the Safety Tolerability and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

This study will assess the safety and tolerability of escalating, multiple ascending doses of Cavosonstat (N91115) in healthy subjects. Approximately 5 ascending cohorts are planned with approximately 8 subjects per cohort (6 active, 2 placebo). Each subject will undergo screening (Day -28 to Day -2) and, if eligible, return to ...